Whitney & Co’s Sarepta Therapeutics SRPT Stock Holding History

Whitney & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12	Closed	-$2K	–	404
2018 Q3	$2K	Buy	+12	New	+$1.64K	﹤0.01%	474

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Whitney & Co's SRPT Position: Q4 2018 in Review

Whitney & Co sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 12 shares — an estimated $2K sold.

Whitney & Co first reported a position in SRPT in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 336 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

Whitney & Co reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 12 Sarepta Therapeutics shares in Q4 2018, an estimated $2K.
Whitney & Co first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 1 quarter.
Whitney & Co's Sarepta Therapeutics position peaked at $2K in Q3 2018.
336 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.